Nestle Grows Skin Care Footprint, Valeant Gains Antitrust Cover In Derma Deal
This article was originally published in The Tan Sheet
Executive Summary
Swiss food and beverage firm Nestle grows its stake in North American skin care with its pending $1.4 billion acquisition from Valeant of five aesthetic dermatology brands, demonstrating its commitment to health and wellness, analysts say. Valeant resolves potential antitrust obstacles to its proposed Allergan acquisition.
You may also be interested in...
Nestle Increases Health Care Investment With Galderma Control
Galderma will be the “foundation” of a new division to be called Nestle Skin Health SA, said Nestle Chairman Peter Brake-Letmathe. L’Oreal will give Nestle its 50% stake in Galderma and $4.6 billion in cash to buy back 8% of its own stock from Nestle.
Valeant Continues Buying Spree With $2.6B Acquisition Of Medicis
The specialty pharma adds to its dermatology portfolio with a proposed acquisition of Scottsdale, Ariz.-based Medicis.
US House Appropriators Seek Data On Fragrance Allergens In Cosmetics, ‘Balance’ In Sunscreen Regs
The House Appropriations Committee asks the US Food and Drug Administration to provide a report to Congress in two years on the resources it would need to develop a database for fragrance allergens used in cosmetics. The committee’s report accompanying FY2023 FDA funding legislation also touches on OTC sunscreen regulation, PFAS in cosmetics, skin-lightening ingredients, and more.